Age, biological sex, and human genetic factors influence the production of antibodies during the immune response. A team of scientists from the Institut Pasteur, the CNRS and the Collège de France ...
In an interview, Jackson Peter Kim, MD, clinical assistant professor in the Division of Nephrology at Stanford Health Care, ...
Innate immunity is a foundational field in immunology, critical for understanding how organisms sense and respond to danger, be it pathogens or sterile ...
Dianthus Therapeutics (NASDAQ:DNTH) executives used a Biotech Summit 2026 discussion to outline upcoming clinical catalysts ...
By far the strongest genetic risk factor for Alzheimer’s disease is a variant of apolipoprotein E, or ApoE. People who carry ...
Everyday Health on MSN
Novel targeted therapies for IgAN: What you need to know
Explore novel therapies for IgA nephropathy that target inflammation and antibody production. Learn how these advancements ...
Comprehensive residue-level mapping of amyloid-beta recognition reveals how sequence variants, post-translational modifications, and aggregation state shape antibody specificity, thereby guiding ...
A new study led by University of Toronto researchers has shown that immune cells in the gut follow an atypical pathway to produce antibodies that provide long-term protection against viruses. The ...
A new approach targets the B-cell pathway with bispecific antibodies, building on decades of research that establishes the role of B cells and self-reactive antibodies in lupus, systemic sclerosis, ...
Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Compass Pathways, which ...
Capturing Unicorns: Targeting Cancers With TP53 Mutations, RAS Alterations Beyond G12C, and MTAP Loss—No Target Is Out of the Realm of Possibility Bispecific antibodies (bsAbs) have emerged as a novel ...
HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio” or the “Company”), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results